Log in
NASDAQ:ELGX

Endologix Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.02
MA: $0.03
$0.22
52-Week Range N/A
VolumeN/A
Average Volume1.28 million shs
Market Capitalization$382,000.00
P/E RatioN/A
Dividend YieldN/A
Beta0.73
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Endologix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200
Employees528

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$143.37 million
Book Value$3.56 per share

Profitability

Net Income$-64,760,000.00

Miscellaneous

Market Cap$382,000.00
Next Earnings DateN/A
OptionableOptionable

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Endologix (NASDAQ:ELGX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Endologix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Endologix
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Endologix?

Wall Street analysts have given Endologix a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Endologix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) announced its quarterly earnings results on Monday, May, 11th. The medical instruments supplier reported ($0.80) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.13. The medical instruments supplier earned $28.51 million during the quarter, compared to the consensus estimate of $28.50 million. Endologix had a negative net margin of 44.65% and a negative return on equity of 63.96%.
View Endologix's earnings history
.

When did Endologix's stock split? How did Endologix's stock split work?

Endologix's stock reverse split on the morning of Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ELGX?

2 equities research analysts have issued twelve-month target prices for Endologix's shares. Their forecasts range from $1.00 to $6.00. On average, they anticipate Endologix's stock price to reach $3.00 in the next twelve months.
View analysts' price targets for Endologix
.

Who are some of Endologix's key competitors?

What other stocks do shareholders of Endologix own?

Who are Endologix's key executives?

Endologix's management team includes the following people:
  • Mr. John Onopchenko, CEO & Director (Age 60)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 50)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 58)
  • Mr. Jeffrey S. Brown, Chief Operations Officer
  • Mr. Jeremy B. Hayden, Gen. Counsel (Age 49)

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How big of a company is Endologix?

Endologix has a market capitalization of $0.00 and generates $143.37 million in revenue each year. The medical instruments supplier earns $-64,760,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Endologix employs 528 workers across the globe.

What is Endologix's official website?

The official website for Endologix is www.endologix.com.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.